icon-charity icon-donate-car icon-energy icon-fundraise icon-shop icon-sponsorships

phase 1

clinical trial

Will combining NK cells from a parent with a humanized antibody be more effective in treating neuroblastoma?

Project Title: hu14.18/IL-2 + KIR ligand mismatch natural killer cells
Researcher: Kenneth B. DeSantes, MD
Institution: University of Wisconsin - Madison
Study Type: Phase I clinical trial
Status: Ongoing

Researchers have made rapid advances in understanding how to manipulate the immune system safely to destroy cancer cells. Adoptive transfer of haploidentical NK (Natural Killer) cells has shown promise as a treatment option to target and kill cancer cells in a less toxic way than conventional therapies. Scientists use a novel technique to collect, expand, and infuse donor NK cells into a patient. Solving Kids’ Cancer supported this trial because researchers use a humanized monoclonal antibody known as hu14.18-IL2, which specifically targets neuroblastoma tumor cells and binds to them. The humanized monoclonal antibody may be more effective at activating the NK cells for killing the cancer cells.

More Clinical Trials

HSV1716 Oncolytic Virus in non-CNS Solid Tumors
Read More >

Vaccine Immunotherapy for DIPG
Read More >

Combining Decitabine and Vaccine Therapy
Read More >

Developing an Anti-ALK Antibody for Neuroblastoma
Read More >